Indian manufacturer of male and female condoms, lubricants and pregnancy test kits, largely sold via government/global tenders.
Indian manufacturer of male and female condoms, lubricants and pregnancy test kits, largely sold via government/global tenders.
Most sales are won in competitive tenders from health ministries and international agencies buying condoms for public health programmes, so volumes are lumpy and depend on winning orders and keeping international quality approvals. Retail and export sales under its own labels are a smaller outlet.
In one line: A niche Indian condom/contraceptive manufacturer.
Moat: narrow (regulatory licence, process know-how). WHO/international pre-qualification and manufacturing scale for female condoms, a niche few make.
Headquarters: Gujarat, India · Founded: 1993 · Employees: 235
Size Cupid (CUPID.NS) is an India Consumer Staples company (Household/Personal Care) with a market value of $5.22B, the 208th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹363.20 on 18 Nov 2026.
Performance Over six months the shares gained 217.7%, against -2.5% for the median peer and +3.8% for the India market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 125.0% over the last twelve months (peer median +6.8%); the operating margin is 32.6% (peer median 12.3%).
Valuation It trades at 88.0× enterprise value to sales against a peer median of 1.9× (most expensive of 21).
Capital Return on invested capital runs 8.1 points above its cost of capital (12.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹5.56B | ₹3.53B | ₹1.81B | ₹1.68B | ₹1.55B |
| Revenue growth | — | +95% | +8% | +8% | — |
| Gross profit | ₹2.63B | ₹1.59B | ₹725M | ₹820M | ₹649M |
| EBITDA | ₹1.87B | ₹1.15B | ₹411M | ₹483M | ₹385M |
| Net income | ₹1.69B | ₹1.08B | ₹409M | ₹399M | ₹316M |
| Free cash flow | n/a | ₹375M | -₹158M | -₹143M | ₹335M |
| Capital expenditure | n/a | ₹247M | ₹195M | ₹250M | ₹25.4M |
| Total debt | ₹1.14B | ₹564M | ₹190M | ₹121M | ₹59.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Cupid CUPID.NS | $5.22B | +218% | +125% | 33% | 88.0× | n/a |
| Reckitt Benckiser RKT.L | $47.5B | +22% | -2% | 28% | 3.3× | 2.1% |
| Okamoto Industries 5122.T | $651M | +13% | +5% | 7% | 0.6× | n/a |
| Church & Dwight CHD | $26.4B | +16% | +2% | 18% | 4.5× | 7.7% |
| Mankind Pharma MANKIND.NS | $11.6B | +5% | +13% | 21% | 7.2× | 28.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CUPID.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.0% | 0.0% | 9th highest of 21 |
| 6-month return | +217.7% | -2.5% | highest of 21 |
| Distance from 52-week high | -7.6% | -21.0% | 7th highest of 21 |
| Revenue growth (TTM) | +125.0% | +6.8% | highest of 21 |
| Operating margin | 32.6% | 12.3% | highest of 21 |
| EV / Sales | 88.0× | 1.9× | most expensive of 21 |
| ROIC minus cost of capital | +8.1 pp | +3.2 pp | 5th highest of 20 |
| Net debt / EBITDA | 0.5× | -0.4× | 7th most indebted of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cupid CUPID.NS | India | $5.22B | +218% | +125% | 33% | 88.0× | n/a | n/a |
| Reynolds Consumer Products REYN | United States | $5.28B | +15% | +2% | 14% | 1.8× | 0.8% | +2.7% |
| Colgate-Palmolive (India) COLPAL.NS | India | $4.91B | -23% | +9% | 28% | 6.9× | 31.1% | +4.5% |
| Mao Geping Cosmetics 1318.HK | Hong Kong | $4.67B | -8% | +32% | 31% | 5.1× | 4.1% | +41.1% |
| Amorepacific 090430.KS | South Korea | $6.01B | 0% | +10% | 9% | 1.6× | 3.6% | -0.8% |
| Interparfums IPAR | United States | $4.28B | +48% | +3% | 18% | 3.0× | 10.5% | +22.5% |
| APR 278470.KS | South Korea | $6.66B | -45% | +119% | 24% | 3.3× | -2.3% | +47.3% |
| e.l.f. Beauty ELF | United States | $6.73B | +124% | +40% | 14% | 3.8× | 24.1% | +38.8% |
| Rohto Pharmaceutical 4527.T | Japan | $3.87B | +8% | +7% | 12% | 1.7× | -2.8% | +13.7% |
| Lion 4912.T | Japan | $3.85B | +44% | +6% | 8% | 1.3× | 0.9% | +3.5% |
| Dabur India DABUR.NS | India | $7.16B | -16% | +9% | 15% | 4.6× | 27.4% | +6.6% |
| Coty COTY | United States | $3.71B | +116% | 0% | 5% | 1.2× | 9.8% | +4.6% |
| Hengan Int'l 1044.HK | Hong Kong | $3.27B | -12% | +2% | 11% | 1.0× | -8.2% | -0.1% |
| Kobayashi Pharmaceutical 4967.T | Japan | $3.25B | +20% | +2% | 6% | 2.8× | 18.0% | +1.9% |
| Proya Cosmetics 603605.SS | China | $2.87B | -13% | +2% | 13% | 1.4× | -5.3% | +23.1% |
| LG H&h 051900.KS | South Korea | $2.81B | -14% | -3% | 3% | 0.4× | -4.6% | -4.1% |
| Godrej Consumer Products GODREJCP.NS | India | $9.75B | -12% | +12% | 18% | 5.6× | 32.9% | +6.6% |
| Gillette India GILLETTE.NS | India | $2.53B | -5% | +8% | 28% | 7.2× | 14.9% | +13.0% |
| Winner Medical 300888.SZ | China | $2.53B | -6% | +4% | 11% | 1.4× | -5.2% | -2.6% |
| Shiseido 4911.T | Japan | $10.8B | +47% | +6% | 6% | 1.9× | 12.7% | +1.0% |
| Cosmax 192820.KS | South Korea | $2.51B | +53% | +25% | 8% | 1.5× | n/a | n/a |